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“Reducing the Risk of 
Surgical Site Infections: 
Will Evidence-Based 
Practices Lead Us to 
the the Promised Land”
Borlaug and Edmiston – AORNJ 2018;107:570-578.
Items For Discussion Today
• Fiscal and Morbid Risk of Surgical Site 
Infections
• Complexity of Surgical Site Infections
• SSI Prevention Guidelines – Mechanistic 
Considerations
• Demystifying the Surgical Care Bundle in 
the Prevention of Surgical Site Bundle
“When They Say it’s Never About the 
Money – It’s Always About the 
Money” – Morbidity versus Fiscal Risk 
for the Patient and Institution
Projected Trends and it is not Pretty
*
1.8 million
4-4.5 million TJRs by 2030
Tisosky et al. J Am Acad Orthop Surgeons 2017;1:e34 
4-4.5 Million Total Joint Implantations per Year by 
2030 – Assuming a 2.18% Infection Rate 
Translates into ~80,000-90,000 PJI
Conservative estimate~$100,000 = 8-9 Billion USD
Less Conservative ~ $400,000 = 32-36 Billion USD
Baseline
• PJI is associated with a 
mortality rate of between 2 –
7%.
• Experts report that the five-year 
survival rate of patients with PJI 
is worse than with most 
cancers.
Edmiston et al,  AJIC 2019: Online In Press
Kurtz et al. J Arthroplasty 2012;27:61-64
Economic Cost of Colorectal Infections
• A retrospective study of patients undergoing CS between 2014 
and 2017 was conducted using IBM® MarketScan® Commercial, 
Multi-State Medicaid and Medicare Supplemental databases
• A total of 83,691 patients were included in the analysis, with mean 
age 56 years (SD:17.3), 53.6% female
• 27.4% cancer patients of which 5.3% with metastatic neoplasms
• 21.5% Medicare and 21.60% Medicaid (all others commercially 
insured)
• 21.2% patients presented with infection: ~84% were identified 
within 60 days of surgery
• 51% of postoperative infections were deep or organ/space.
• Adjusted total payments in patients with commercial insurance 
mean cost $185,435 (95% CI: $163,586-$210,202) for deep/organ 
space infections ($1.7e9 national cost / $2.6e6 institutions at 
risk).
Edmiston et al.  Colorectal Surgery: Risk and Burden of Post-Surgical Organ Space, Deep and 
Superficial Infection. ISPOR May 2019, Las Vegas, NV
“The practice of evidence-based medicine means 
integrating individual clinical expertise with the best 
external evidence from systematic reviews.”
Sackett et al. Evidence-based medicine: what it is and what it isn’t. BMJ 1996;312:71-72
“….all surgical wounds are contaminated to some degree at closure – the 
primary determinant of whether the contamination is established as a 
clinical infection is related to host (wound) defense”
Belda et al., JAMA 2005;294:2035-2042
“It’s all about the 
surgical wound”
The Fundamental Problem
Recognition of the surgical locus of infection influences the 














The Complexity of Risk - Classification 
of Surgical Site Infections (SSI)
Mangram AJ, et al. Am J Infect Control 1999;27:97-132
Major Barriers to Improvement
• Poor compliance
• Lack of shared goals and 
priorities
• Poor communication
• Less than robust institutional 
commitment
So what is the weakest link?
• Patient who smoked (7.4% vs 4.8%; 
p = 0.04), 
• Patients who abused alcohol (10.6% vs 
5.7%; p = 0.04)
• Patients with type 2 diabetics (8.8% vs 
5.5%; p = 0.046)
• Obese patients (11.7% vs 4.0%; p< 0.001). 
• Surgical site infection rates higher 
Operation duration longer than 140 
minutes (7.5% vs 5.0%; p= 0.05) 
These risk factors were also associated with an 
increase in SSI rates as a compounded score 
(P < 0.001). 
• Patients with 1 or fewer risk factors 
(n = 427) - SSI rate of 2.3%
• Patients with 2 risk factors (n = 445) – SSI 
rate 5.2% 
• Patients with 3 factors (n = 384) had a 
7.8% SSI rate 




A More Than a Typical Scenario –
What is the True Risk of Infection?
High Risk Patient: 
Immunosuppressive meds - RA
Diabetes
Advanced age
Prior surgery to same joint
Psoriasis
Malnourished 
morbid obesity                                                                     
sAlb<35
low sTransferrin
Remote sites of infection
Smokers
ASA ≥3




Courtesy of Maureen Spencer
Caprice Greenberg, MD – SSI Summit V Madison, WI  - September 29, 2017
Are SSI Prevention Guidelines 
Helpful – A Mechanistic Basis
Comparative Analysis of WHO, Proposed CDC, ACS and 
Wisconsin SSI Prevention Guidelines
INTERVENTION WHO 
Guidelines




Maintain normothermia Maintain normothermia Maintain normothermia -
FAW reduces incidence 
of SSI = 1A
Wound Irrigation No recommendation Intraoperative irrigation 
recommended - povidone 
iodine





Short durational Short durational Short durational Short durational – Follow 
ASHP weight-based 
dosing = 1A
Glycemic Control Recommended Recommended – No 
recommendation for 
HA1c
Highly beneficial Highly beneficial 
HbA1c <7 (<154)
<8 (<183) = 1A
Perioperative 
Oxygenation
Recommended Administer increased   




Strongest (High – 1A)
for colorectal surgery
Preadmission Showers Advised patients to 
bathe or shower with 
soap
Advise patients to bathe 
or shower with soap or 
antiseptic agent –at least 
night before surgery




4% or 2% CHG night 
before/morning (High)
Antimicrobial Sutures Use antimicrobial 
sutures independent
of type of surgery
Consider use of triclosan-
coated sutures for 
prevention of SSI
Recommended for clean and 
clean-contaminated 
abdominal procedures
The use of triclosan 
sutures represents = 1A 
clinical evidence
Percent Therapeutic Activity of Serum / Tissue Concentrations Compared 
to Surgical Isolate (2002-2004) Susceptibility to Cefazolin Following 2-gm 
Perioperative Dose
Organisms n Serum Tissues
Staphylococcus aureus 70 68.6% 27.1%
Staphylococcus epidermidis        110 34.5% 10.9%
E. coli 85 75.3%            56.4%
Klebsiella pneumoniae 55 80% 65.4%
Edmiston et al, Surgery 2004;136:738-747
Perioperative Antimicrobial Prophylaxis in Higher BMI 
(>40) Patients: Do We Achieve Therapeutic Levels?
Does BMI Increase Risk?
Toma et al., Anesthesia Analgesia 2011;113:730-737
• “Measured and dose-normalized 
subcutaneous cefoxitin 
concentrations and AUCs in the 
obese patients were significantly 
lower than in the normal-weight 
subjects. 
• There was an inverse relationship 
between cefoxitin tissue penetration 
(AUC tissue/ AUC plasma ratio) and 
body mass index. 
 Tissue penetration was 
substantially lower in the obese 
patients compared to normal weight 
controls (p = 0.05).”
• “This occurred despite 2-fold-
higher cefoxitin dosage (1 to 2 
gms). 
 Diminished tissue antibiotic 
concentrations in morbid obesity 





Microbial Ecology of Skin Surface
• Scalp 6.0 Log10 cfu/cm
2
• Axilla 5.5 Log10 cfu/cm
2
• Abdomen 4.3 Log10 cfu/cm
2
• Forearm 4.0 Log10 cfu/cm
2
• Hands 4.0-6.6 Log10 cfu/cm
2
• Perineum  7.0-11.0 Log10 cfu/cm
2
Surgical Microbiology Research Laboratory – Medical College of Wisconsin
Mean Chlorhexidine Gluconate (CHG) Skin Surface 
Concentrations (µg/ml+SD) Compared to MIC90 (5 µg/ml) 
for Staphylococcal Surgical Isolates Including MRSAa
Subgroups (mean C, µg/ml)
Pilotb 1                     2
Groups              (4%)    (4% Aqueous)   (2% Cloths)            [CCHG/MIC90]             p-value
Group A (20)
evening (1X)  3.7+2.5       24.4+5.9       436.1+91.2           0.9      4.8      87.2         <0.001
Group B (20)
morning (1X)  7.8+5.6      79.2+26.5      991.3+58.2          1.9     15.8    198.2        <0.0001
Group C (20)
both (2X)        9.9+7.1     126.4+19.4    1745.5+204.3 2.5     25.3     349.1       <0.0001
a N = 90
b Pilot group N = 30
Edmiston et al, J Am Coll Surg 2008;207:233-239
Edmiston et al, AORNJ 2010;92:509-518  
Looking at the Preadmission Shower 




To Maximize Skin Surface Concentrations of CHG –
A Standardize Process Should Include
• Dose - 4-ozs. for each shower
• Timing - 1-minute pause before rinsing (4% CHG)
• Duration - TWO SHOWERS (CLEANSINGS) –
NIGHT BEFORE/MORNING OF SURGERY
• An SMS, text or voicemail reminder to shower
• A standardized regimen – instructions – Oral and 
written
CHG conc ≥1000 µg/ml
Remember the devil is always in the details
4% Aqueous CHG
Edmiston et al.  JAMA Surg 2015;150:1027-1033
Making an Evidence-Based Argument – Can We 
Validate the Efficacy of an Antimicrobial 
(Triclosan) Wound Closure Technology?
Late-Onset Vascular Graft Infection
Mean Microbial Recovery from Standard Polyglactin






















































Edmiston et al,  J Am Coll Surg 2006;203:481-489

Presence of Biofilm on Selected Sutures from Non-

















anon-infected nylon suture segments were randomly selected for microscopy, culture positive
binfected braided suture segments were randomly selected for microscopy
cinfected monofilament suture segments were randomly selected for microscopy
Non-Infected Cases Infected Cases 





Edmiston, Krepel, Marks, Rossi, Sanger, Goldblatt, Seabrook.  J Clin Microbiol 2013;51:417 
Edmiston et al., Surgery 2013;154;89-100 Wang et al., British J Surg 2013;100;465-473
What Do the Various Meta-Analyses Tell Us About 
Triclosan Suture as a Risk Reduction Strategy?
• 2013 - Sajid et al, Gastroenterol Report 2013:42-50: 7 RCT (1631 patients) –
Odds of SSI 56% less in triclosan suture group compared to controls (p<0.04)
• 2013 - Wang et al, BJS 2013;100-465: 17 RCT (3720 patients) – 30% decrease in 
risk of SSI (p<0.001)
• 2013 - Edmiston et al, Surgery 2013;154:89-100: 13 RCT (3568 patients) – 27% 
to 33% decrease in risk of SSI (p<0.005)
• 2014 - Daoud et al, Surg Infect 2014;15:165-181: 15 RCT (4800 patients) – 20% 
to 50% decreased risk of SSI (p<0.001)
• 2015 - Apisarnthanarak et al. Infect Cont Hosp Epidemiol 2015;36:1-11: 29 
studies (6,930 patients) – 26% reduction in SSI (p<0.01)
• 2016 - Guo et al, Surg Research  2016; doi:10.1016/j.jss.2015.10.015 – 13 RCT 
(5256 patients) (risk ratio [RR] 0.76, 95% confidence interval [CI] 0.65e0.88, p < 
0.001)
• 2017 – Wu et al, Eur J Clin Microbiol Infect Dis 2017;36:19-32: 13 RCT (5,346 
patients) (risk ratio [RR] 0.72,95% confidence interval [CI] 0.59-0.88, p<0.001)
• 2017 – De Jonge et al, BJS 2017;104:e118-e133: 21 RCT (6,462 patients) (risk 
ratio [RR] 28% reduction, 95% confidence ratio [CI] 0.60-0.88, p<0.001)
Daoud, Edmiston, Leaper  - Surgical Infections 2014;15:165-181
Multiple Clinical Studies Have 
Documented That Triclosan-
Coated Sutures Provide A 




• And Contaminated Surgical 
Procedures 
Safety (~ 1 Billion strands)
• No MAUDE (FDA) reports (16 years) documenting significant evidence linking 
triclosan to adverse impact in surgical wounds; No evidence of pediatric toxicity, 
Renko et al. Lancet Infectious Disease 2016;17:50–57; No evidence of human 
toxicity following oral or dermal exposure, Roidricks et al. Crit. Rev. Toxicol. 
2010;40:422. doi: 10.3109/10408441003667514.
Microbicidal Activity (Spectrum)
• Gram-positive and Gram-negative antimicrobial activity - No published studies 
have demonstrated that use of triclosan coated sutures are associated with the 
emergence of resistant surgical pathogens.
Evidence-based Clinical Effectiveness (Meta-Analysis)
• Currently 13 meta-analysis in the peer-literature document clinical efficacy of 
triclosan (antimicrobial) suture technology.
Cost-Effectiveness
• Two recent studies, [Singh et al. Infect Control Hosp Epidemiol 2014;35:1013; 
Leaper and Edmiston. British Journal Surgery 2017;104:e134-e144] document 
that use of triclosan-coated sutures provides significant fiscal benefit to hospital, 
third party-payer and patient.
How Does One Evaluate An Antimicrobial Risk -
Reduction Technology – The Triclosan Suture Story?
17 Year Evidence-Based Journey
Embracing a Surgical Care Bundle
Mitigating Risk - Surgical 
Care Improvement Project 
(SCIP) – An Evidence-Based 
Approach
• Timely and appropriate 
antimicrobial prophylaxis 
• Glycemic control in cardiac 
and vascular surgery 
• Appropriate hair removal
• Normothermia in general 
surgical patients
Is this the Holy Grail?
Waits et al, Surgery 2014;155:602




Johnson et al. Obstet Gynecol 2016;127:1135-1144
Putting it all Together – Demystifying 
the Surgical Care Bundle
















2% / 4% CHG
Preadmission
Shower/cleansing
















TrayModerate to High (1A)
Level of Evidence-Based 
Documentation
Mechanical
Bowel Prep  
Oral
Antibiotics
Again, So How Do We Use All of This 
Information?
Baseline Evidence-Based Interventions – Designated High-1A** 
• Normothermia – 1A
• Perioperative antimicrobial prophylaxis – Weight-based – 1A
• Antimicrobial (triclosan) coated sutures (fascia / subcuticular closure) – 1A
• Preadmission CHG shower/cleansing – Standardized regimen – 1A
• Perioperative antisepsis – 2% CHG/ 70% alcohol – 1A
• Glycemic control – 1A
• Separate wound closure tray - High
• Glove change prior to fascia/subcuticular closure - High
Inclusive Evidence-Based Intervention for Consideration in 2019**
• Supplemental oxygen – Colorectal – 1A
• Oral antibiotics / Mechanical bowel prep – Colorectal – 1A
• Wound edge protector – Colorectal – 1A
• Staphylococcal decolonization – Orthopedic / CT  - 1A 
• Smoking cessation – 1A
• Irrigation with 0.05% CHG  - Moderate 
• OR traffic control – Device-related procedures – Low
Building an Effective Surgical Care Bundle*







Less bleeding / preserve immune 
function in wound bed / enhanced 
wound healing
Perioperative antimicrobial prophylaxis –
“Weight-based” 
1A
Tissue antisepsis / intraoperative 
conc > MIC90 wound pathogens
Glycemic control  
1A
Preserve granulocytic immune 
function / enhance wound healing
Antimicrobial (triclosan) coated sutures 
(fascia / subcuticular closure) 1A
Mitigate nidus of infection / local 
tissue antisepsis
Preadmission CHG shower / cleansing High-
1A 
Skin antisepsis / reduce skin 
bioburden
Perioperative skin-prep – 2% CHG / 70% 
alcohol 
1A
Skin antisepsis / reduce skin 
bioburden
Separate wound closure tray 
High
Mitigate instrument contamination
Glove change prior to fascia / subcuticular 
closure 
High
Disrupt cross-contamination across 
tissue planes






Supplemental oxygen – Colorectal 
1A
Enhanced tissue oxygenation 
and immune function / metabolic 
benefits / wound healimg
Oral antibiotics / Mechanical bowel prep –
Colorectal 
1A
Reduce bioburden within the 
bowel lumen and on brush 
border surfaces
Wound edge protector – Colorectal, 
vascular, OB/GYN
1A
Intraoperative wound antisepsis 
/ minimizing wound 
contamination
Staphylococcal decolonization – Orthopedic 
and CT 
1A Mitigate S. aureus and MRSA 
pathogenicity
Smoking cessation – Orthopedic, Neuro, 
CT - likely all surgical procedures
1A
Preserve angiogenesis /reduce 
risk of dehiscence / enhance 
wound healing
Intraoperative irrigation of the surgical 
wound with 0.05% chlorhexidine gluconate
Moderate
Mitigate wound contamination 
prior to closure 
OR traffic control – minimize door openings Low to 
Moderate
Reduce OR air bioburden
The  Mechanistic Benefit of Oral 
Antibiotics and Mechanical Bowel Prep
Arch Surg. 1989;124:281-284
Englesbe et al . A statewide assessment of surgical site 
infection following colectomy: the role of oral antibiotics. 
Ann Surg. 2010;252:514-9
Groner, Edmiston, Krepel et al. Arch Surg. 1989;124:281
Edmiston CE et al. World Journal of 
Surgery 1990;14: 176–183





























































• NGT / Drains
• MIS
• Near infrared vascular 
imaging
• Wound Protector
• Wound Closing Protocol
• Wound management
• Residual neuromuscular 
weakness
• Wound classification
Source: Marc Singer, MD, FAC, SSI Symposium VI
September 21, 2018 – Wisconsin Dells, WI
A Brief Story
Leaper et al. Int Wound J. 2014 Feb 25. doi: 10.1111/iwj.12243
The Absolute Weakest Link
Do Surgical Care Bundles Provide 
A Fiscal Benefit?
Colorectal Scenario:
Is There A Fiscal Benefit 




$185,435 (mean cost of deep/organ 
space SSI) *
$50 per surgery (cost of surgical 
care bun dle)
$185,435 / $50 = 3,708 procedures
3,708 / 200 cases ~ 18.5 years
4,635 / 500  cases ~ 7.4 years
Scenario #2
$25,000 (mean cost of superficial, 
deep and organ/space SSI)
$25,000 / $50 = 500 procedures
500 / 200 cases ~ 2.5 years
500 / 500 cases ~ 1 years
* Edmiston et al. ISPOR May 2019, New Orleans, LA
** CDC estimated cost 
SSI Prevention Is Not a Solo Recital 
But Rather a Symphony and We Are 
All Part of the Orchestra
Thank You
